The TBP strategy failed to improve PFS in patients with HER2-positive advanced G/GEJ cancer, and no beneficial biomarkers were found.
No takes yet. Share an insight, caveat, or question.
Makiyama et al. (2020) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: